CUBTCURATIVE BIOTECHNOLOGY INC.

About CURATIVE BIOTECHNOLOGY INC. (CUBT)

CURATIVE BIOTECHNOLOGY INC. (CUBT) is a Biotechnology company headquartered in Palm Beach Gardens, FL, United States whose shares trade over-the-counter on the Pink tier.

Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech currently has ongoing programs in three (3) different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. The Company is now concentrating its energy and resources on its degenerative eye disease platform, based on a worldwide exclusive license from the National Eye Institute (NEI) at the National Institutes of Health (NIH). The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD) disease with the goal of being in the clinic in 2025 for a first in human trial of its metformin-based eye drop. The trial will be conducted under a Cooperative Research and Development Agreement (CRADA) with the NEI.

Products and services

The Company is focused on developing therapies with potentially accelerated development paths as a result of either the disease, the nature of the therapeutic itself, or the stage of clinical development. The Company operates on an outsource model, where it’s core management group oversees a network of subject matter experts, clinical advisors, manufacturing vendors and regulatory consultants.

CUBT key facts

Ticker symbol

CUBT

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Palm Beach Gardens, FL, United States

Country of incorporation

US

Year of incorporation

2007

Employees

3

Estimated market cap

$14.44M (as of Apr 10, 2025)

Shares outstanding

969,263,384

Reporting standard

Alternative Reporting Standard

Audit status

Unaudited

Fiscal year end

12/31

Latest filing

Quarterly Report (Sep 30, 2024)

CURATIVE BIOTECHNOLOGY INC. leadership

• Paul M Michaels — Co-CEO, President
• I. Richard Garr, J.D. — Co-CEO, General Counsel
• Ronald W. Bordens, Ph.D. — EVP, Eng.& Ops.
• Michael J. Grace, Ph.D. — Advisor
• Kapil Bharti, Ph.D. — Advisor
• Nicholas Boulis, M.D., Ph.D. — Advisor
• Barry A Ginsberg, O.D. — Consultant
• Meg Powell — Other

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with C